Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02359097 · ClinicalTrials.gov registry record · NA
Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma
A NA study, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 29
- Enrollment target
NCT02359097 is a NA study that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 29 participants.
The verdict
NCT02359097, a NA study, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
Study Summary
This clinical trial studies steady state blood volume maps using ferumoxytol non-stoichiometric magnetite magnetic resonance (MRI) in imaging patients with glioblastoma. MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. Contrast agents, such as ferumoxytol non-stoichiometric magnetite, may enhance these pictures and increase visibility of tumor cells and the blood vessels in and around the tumors.
Interventions
- DRUG Ferumoxytol
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
- DRUG Gadoteridol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2015-01-06 |
| Est. Completion | 2021-03-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02359097
The ClinicalTrials.gov registry entry for NCT02359097 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ferumoxytol is the first listed.
NCT02359097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02359097 about?
NCT02359097 is a clinical study titled "Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma". This clinical trial studies steady state blood volume maps using ferumoxytol non-stoichiometric magnetite magnetic resonance (MRI) in imaging patients with glioblastoma. MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas i...
What is the current status of trial NCT02359097?
This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2015-01-06. Estimated completion is 2021-03-12.
What interventions are being tested in trial NCT02359097?
The interventions under investigation include: Ferumoxytol (DRUG), Magnetic Resonance Imaging (PROCEDURE), Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE), Gadoteridol (DRUG).
Who is sponsoring clinical trial NCT02359097?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.